| Name | Title | Contact Details |
|---|
Cerno Bioscience is a company that develops and publishes mass spectrometry calibration and analysis software that extends the limits of mass spectrometry.
Personal Genome Diagnostics (PGDx) is empowering the fight against cancer by unlocking actionable information from the genome. We are committed to developing a portfolio of regulated tissue-based and liquid biopsy genomic products for laboratories worldwide. Our expertise in advanced cancer genome analysis ranges from sample preparation and sequencing to data interpretation and analysis. We specialize in high-throughput next-generation sequencing, proprietary algorithms to identify alterations in complex cancer genomes and have developed novel technologies for non-invasive approaches in cancer. PGDx was founded in 2010 by Luis Diaz and Victor Velculescu to help bring novel diagnostic approaches to patients with cancer. They are internationally recognized leaders in cancer genomics who have extensive experience in the application of innovative genomic technologies for drug development and clinical practice.
Quadrant Biosciences is an epigenetic diagnostics company with a focus on the early detection of neurological disorders and other large-scale health issues. Revolutionary advancements in the early detection of autism spectrum disorder, Parkinson’s disease, and mTBI, through the application of the Clarifi® epigenetic diagnostic platform, could have a significant impact on the way clinicians approach the diagnosis and treatment of these serious conditions. In March 2020, we made the decision to pivot and allocate some of our resources to directly address the pandemic. By leveraging our expertise in RNA analysis, we have been able to be part of three exciting COVID-19 projects to aid in the detection of COVID-19 in individuals and communities across the U.S.
AbCellera is a technology company that searches, decodes, and analyzes natural immune systems to find antibodies that its partners can develop into drugs to prevent and treat disease. Its full-stack, AI-powered drug discovery platform integrates modern technologies from engineering, microfluidics, single-cell analysis, high-throughput genomics, machine learning, and hyper-scale data science. We partner with drug developers of all sizes, from large pharmaceutical to small biotechnology companies, empowering them to move quickly, reduce costs, and tackle the toughest problems in drug development.
We are pleased to offer clinicians the first of many advances, the GI-MAP™. The GI-MAP™ (GI-Microbial Assay Plus) stool test utilizes cutting edge, FDA-approved technology to provide a true DNA/PCR based stool analysis which provides actionable informa...